|
An experimental immunotherapy against leukemia using genetically modified T-cells developed by Cellectis. Unlike personalized medicine, UCART19 is hoped to be “off-the-shelf”.〔()〕 Developed for Chronic lymphocytic leukemia (CLL) and Acute lymphoblastic leukemia (ALL)〔()〕 ==See also== *CAR-T 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「UCART19」の詳細全文を読む スポンサード リンク
|